Activation of XXXX / @entity6897 signalling predicts response to chemotherapy in @entity2931 receptor-negative @entity0 .

@entity1 @entity0 @entity2931 @entity5 @entity19 @entity379 @entity6897 @entity3027
BACKGROUND: @entity2931 receptor-negative (ER-) @entity0 is intrinsically sensitive to chemotherapy. However, @entity5 response is often incomplete, and relapse occurs with high frequency. The aim of this work was to analyse the molecular characteristics of @entity5 and early response to chemotherapy in @entity1 -derived xenografts (PDXs) of @entity0 . METHODS: Gene and protein expression profiles were analysed in a panel of ER- @entity0 PDXs before and after chemotherapy treatment. @entity5 and stromal @entity379 expression was measured in xenografts lysates by @entity1 and @entity19 cytokine arrays, respectively. RESULTS: The analysis of @entity5 cells in chemo-responder PDX revealed a strong overexpression of @entity3027 -inducible genes, induced early after AC treatment and associated with increased @entity6897 phosphorylation, DNA-damage and apoptosis. No increase in @entity3027 -inducible gene expression was observed in chemo-resistant PDXs upon chemotherapy. Overexpression of @entity3027 -related genes was associated with @entity1 @entity379 secretion by @entity5 cells. CONCLUSIONS: Treatment-induced activation of the @entity3027 / @entity6897 pathway in @entity5 cells is associated with chemotherapy response in ER- @entity0 . Further validations in prospective clinical trials will aim to evaluate the usefulness of this signature to assist therapeutic strategies in the clinical setting.
